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Oxidative stress plays a central role in the pathogenesis of diverse chronic inﬂammatory disorders in-
cluding diabetic complications, cardiovascular disease, aging, and chronic kidney disease (CKD). Patients
with moderate to advanced CKD have markedly increased levels of oxidative stress and inﬂammation
that likely contribute to the unacceptable high rates of morbidity and mortality in this patient popula-
tion. Oxidative stress is deﬁned as an imbalance of the generation of reactive oxygen species (ROS) in
excess of the capacity of cells/tissues to detoxify or scavenge them. Such a state of oxidative stress may
alter the structure/function of cellular macromolecules and tissues that eventually leads to organ dys-
function. The harmful effects of ROS have been largely attributed to its indiscriminate, stochastic effects
on the oxidation of protein, lipids, or DNA but in many instances the oxidants target particular amino
acid residues or lipid moieties. Oxidant mechanisms are intimately involved in cell signaling and are
linked to several key redox-sensitive signaling pathways in ﬁbrogenesis. Dysregulation of antioxidant
mechanisms and overproduction of ROS not only promotes a ﬁbrotic milieu but leads to mitochondrial
dysfunction and further exacerbates kidney injury. Our studies support the hypothesis that unique re-
active intermediates generated in localized microenvironments of vulnerable tissues such as the kidney
activate ﬁbrogenic pathways and promote end-organ damage. The ability to quantify these changes and
assess response to therapies will be pivotal in understanding disease mechanisms and monitoring efﬁ-
cacy of therapy.
& 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Oxygen forms the basis of aerobic life but, it is well-recognized
that it can be modiﬁed by cellular metabolism to form highly re-
active free radicals termed as “reactive oxygen species” (ROS)
which in turn can form a variety of intermediates including “re-
active nitrogen species” (RNS). Oxidative stress may be viewed as
an essential consequence related to the fundamental biological
need for utilization of molecular oxygen (O2) for energy produc-
tion from simple aerobic eukaryotes to more complex mammalian
species [1]. While physiological levels of such oxidants have a
beneﬁcial role in energy production, cellular signaling and host
defense, excess oxidants can lead to pathological consequences.
Acute kidney injury (AKI) is characterized by the sudden de-
terioration of kidney function and is associated with a high in-
cidence of morbidity and mortality [2]. Chronic kidney disease
(CKD) affects approximately 26 million people in the US and
premature death from cardiovascular disease and from all causes
is higher in adults with CKD compared to adults without CKD [3].
During the past decade these two syndromes were conceptually
distinct, however, evidence from experimental models and recent
epidemiological studies suggest that AKI and CKD are closely in-
terconnected: AKI can result in end-stage kidney disease (ESKD),
AKI is a risk factor for CKD, CKD is a risk factor for AKI, and both
are risk factors for cardiovascular disease [2,4]. The exact me-
chanisms by which AKI initiates or accelerates CKD in humans are
unknown and as a result there are currently no therapies to halt or
reverse AKI or to address the relentless progression of CKD.
Fibrosis is characterized by maladaptive wound repair follow-
ing tissue injury that leads to the progressive accumulation of
interstitial matrix proteins with gradual destruction of renal tu-
bules and functional nephrons. Increased oxidative stress is a
consistent characteristic of both AKI and CKD. Although once
conceptualized as a random process, it is now recognized that
oxidant-mediated injury occurs along predictable pathways and
through speciﬁc cell types. One of the ways that oxidant and an-
tioxidants may affect disease pathogenesis is through the mod-
ulation of reversible oxidation-reduction (redox) processes. Redox
is a dynamic process that involves the ROS/RNS to oxidize a critical
protein, such as a kinase, phosphatase or enzyme, and an anti-
oxidant, typically a thiol containing protein such as glutathione
(GSH) to reduce the protein back to its original state [5,6]. Redox
signaling is advantageous because ROS/RNS are diffusible, per-
mitting action at a distance. In this review, we will discuss the
major oxidant and redox sensitive pathways in kidney injury and
ﬁbrosis.2. Oxidative regulation of the ﬁbrotic response
Oxidative stress is commonly viewed as a disturbance in the
balance between oxidant production and antioxidant defense
mechanisms within the tissue. Both acute and chronic kidney in-
jury are characterized by an over-production of oxidants in the
presence of a diminished antioxidant reserve. This imbalance of
pro-oxidants or free radicals can oxidize macromolecules such as
proteins, lipids, and nucleic acids altering redox sensitive path-
ways resulting in subsequent cell and tissue injury (Fig. 1).Reactive oxygen species (ROS) and reactive nitrogen (RNS) are
collective terms that include not only highly reactive oxygen and
nitrogen radicals (O2 , OH, and NO derived NO2) but also non-
radical derivatives (ONOO). Several enzyme complexes generate
ROS and RNS such as NADPH oxidase, myeloperoxidase, nitric
oxide synthase, and superoxide dismutase. Although many of
these oxidant complexes are important in kidney injury [7], we
will focus on oxidant pathways most thoroughly investigated in
regards to redox regulation in kidney disease.
2.1. NADPH oxidase
Superoxide anion (O2) is the major free radical generated in-
vivo through the action of the enzyme complex, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase. The phagocyte
NADPH oxidase enzyme complex is composed of the membrane
bound ﬂavocytochrome subunits Nox (formerly known as
gp91phox) and p22phox and cytosolic regulatory proteins p47phox,
p67phox, p40phox, and the GTPase Rac1/2. All Nox proteins contain a
heme binding site on a membrane spanning region of the
N-terminal half and NADPH- and FAD-binding domains in the
C-terminal half. Membrane bound Nox along with p22phox form
the catalytic core that can transfer electrons across biological
membranes using NADPH as the electron donor to molecular O2 to
generate superoxide anion (O2). At neutral pH, O2 is a redu-
cing agent rather than an oxidant. However, O2 dismutates
enzymatically or nonenzymatically into hydrogen peroxide (H2O2),
which can then oxidize thiol residues, a mechanism for cellular
signaling via the inactivation of cysteine-containing phosphatases
[8]. It can also function as an oxidizing substrate for heme proteins
such as myeloperoxidase (MPO). O2 also reacts at a diffusion-
controlled rate with nitric oxide (NO) to form peroxynitrite
(ONOO), a powerful reactive nitrogen species that nitrates tyr-
osine residues on proteins and may induce oxidative damage to
other macromolecular substrates.
Nox and p22phox are activated after recruitment and phos-
phorylation of the three regulatory proteins (p47phox, p67phox,
p40phox) and the GTPase Rac1/2, which assemble with the mem-
brane-bound proteins to form a functional NADPH oxidase [9,10].
This regulatory pathway allows Nox to remain inactive in resting
cells and rapidly activated to provide the respiratory burst in
leukocytes or ROS in nonphagocytic cells.
There are currently seven Nox isoforms (Nox1-5, Duox1,
Duox2). Several Nox isoforms (Nox1-4) share a number of critical
structural and functional domains with Nox2. Excessive produc-
tion of ROS by the Nox complex is commonly thought to be re-
sponsible for tissue injury associated with a range of chronic in-
ﬂammatory diseases and has long been considered a unique
property of phagocytic cells. Deﬁciency of Nox2 in humans results
in chronic granulomatous disease characterized by multiple ab-
scess formation due to inability to remove bacterial pathogens.
However, in animal studies of chronic injury, Nox2 deﬁciency was
associated with enhanced inﬂammation with subsequent tissue
damage [11–15], implying that Nox2 also has beneﬁcial functions
in immune responses and cell signaling. Recent studies have
broadened our understanding of Nox’s function to include cellular
processes as diverse as cell proliferation, migration, differentiation,
signal transduction, and oxygen sensing [9,16,17].
Fig. 1. Redox Pathways and Kidney Injury. Under normal physiological conditions, redox reactions are balanced and cellular homeostasis is preserved. With pathological
stimuli, renal cells produce oxidants in an uncontrolled manner which can lead to irreversible cellular damage due to oxidation of proteins and lipids resulting in kidney
injury. Thiol oxidation in proteins is depicted as an illustrative example in the ﬁgure. AMPK, 5′ adenosine monophosphate-activated protein kinase; AGEs, advanced
glycosylation end-products; eNOS, endothelial nitric oxide synthase; HETE, Hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; Mito, mitochondrial electron
transport chain; MPO, myeloperoxidase; NOX, NADPH oxidase; PTEN, Phosphatase and tensin homolog; PUFA, polyunsaturated fatty acids; ROS, reactive oxygen Species;
RNS, reactive nitrogen species.
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Nox proteins are increasingly recognized as important media-
tors and modulators of speciﬁc intracellular signal transduction
pathways by activating redox-sensitive kinases. Potential media-
tors include angiotensin II, endothelin-1, hypercholesterolemia,
shear stress, non-esteriﬁed fatty acids, hyperglycemia, and growth
factors that can also augment Nox activity. Angiotensin II may
represent a pathophysiologically relevant pathway for stimulating
the production of reactive intermediates in the kidney because
inhibitors of this pathway lower the risk for renal progression [18].
Nox4 appears to produce a higher H2O2 to superoxide ratio com-
pared to Nox1, Nox2, and Nox5. Studies strongly suggest that H2O2
formation occurs via the third extracytosolic loop (E-loop) of Nox4
that is 28 amino acids longer than that of Nox1 or Nox2. The
E-loop of Nox4, in contrast to Nox1 and Nox2, contains highly
conserved histidine that could serve as a source of protons to ac-
celerate spontaneous dismutation of superoxide to form H2O2 [19].
Nox4 is the predominant form in the kidney due to its expression
in proximal tubules and is up-regulated in renal tubular epithelial
cell injury and diabetic nephropathy. Nox4 is also present in po-
docytes, mesangial cells, and microvascular endothelial cells
making it a key oxidation complex in the kidney.
Mesangial cell hypertrophy and podocyte injury are two im-
portant disease promoting pathways in the progression of diabetic
nephropathy and other glomerular diseases, the leading causes of
chronic kidney disease and end-stage kidney disease. In cultured
mesangial cells, glucose elicits a rapid upregulation in Nox4 pro-
tein levels, including in the mitochondrial fraction and is asso-
ciated with an increase in cellular and mitochondrial ROS pro-
duction [20–22]. In diabetic nephropathy and other kidney dis-
eases, Angiotensin II (Ang II) activates glomerular mesangial cellsand leads to hypertrophy and extracellular matrix accumulation.
Ang II induces an increase in 3-phosphoinositide-dependent pro-
tein kinase-1 (PDK-1) kinase activity that requires phosphorylation
on tyrosine 9 and 373/376. Mutation of these tyrosine sites blocks
AngII-dependent mesangial cell hypertrophy and ﬁbronectin ac-
cumulation. The tyrosine kinase Src is upstream of PDK-1 and is
the site of redox regulation. Small interfering RNA for Nox4 in-
hibits Ang II-induced activation of Src and PDK-1 tyrosine phos-
phorylation [23].
Nox4 localizes to mitochondria in mesangial cells and the cortex
of the kidney and silencing of Nox4 blocks glucose-induced mi-
tochondrial superoxide generation [20]. In cardiac myocytes, over-
expression of Nox4 leads to an increase in ROS oxidation of cysteine
residues in mitochondrial proteins [24]. In endothelial cells, Nox4
depletion induced alterations in mitochondria morphology, stabi-
lized mitochondrial membrane potential, and decreased production
of H2O2 and that Nox4-derived ROS decreased mitochondrial
function via disruption of the electron transport chain I. These
ﬁndings suggest that mitochondrial electron transport chain may be
a downstream effector of Nox4. In addition, two recent studies
demonstrated that another important downstream target of Nox4-
derived ROS is the uncoupling of endothelial nitric oxide synthase
(eNOS) and a decrease in nitric oxide (NO) bioavailability [21,25].
Lee and colleagues demonstrated that mesangial cell ﬁbronectin
production induced by Ang II involved the reaction of Nox4-derived
superoxide with eNOS-derived NO resulting in ONOO that sub-
sequently uncouples eNOS further promoting superoxide genera-
tion [25]. Eid and colleagues demonstrated in a rat model of dia-
betes that Nox4-dependent eNOS uncoupling induced by hy-
perglycemia not only eliminates the protective effect of eNOS-de-
rived NO but enhances ROS generation and the mesangial cell
ﬁbrotic response. They further identiﬁed two novel upstream
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(AMPK) [21]. Sestrin 2 and AMPK are important for the main-
tenance of metabolic homeostasis and also function as stress-in-
ducible proteins that are critical for the suppression of ROS pro-
duction and protection from oxidative stress [26–29]. Sestrin
2 counteracts Nox4-derived ROS production by blocking the rapid
upregulation of Nox4 protein elicited by hyperglycemia. AMPK
mediates the inhibitory effects of Sestrin 2 on hyperglycemia-sti-
mulated and Nox4-dependent eNOS dysfunction and extracellular
matrix protein accumulation in mesangial cells. In summary, hy-
perglycemia promotes AMPK inactivation via downregulation of
Sestrin 2, which leads to increased Nox4 and Nox4-derived ROS
production followed by eNOS uncoupling and a decrease in NO
bioavailability and enhancement of the mesangial cell ﬁbrotic
response.
Podocytes demand a high energy supply that is primarily
derived from the respiratory chain of mitochondria to maintain
cellular functions like the organization of cytoskeletal and other
extracellular matrix proteins. Dysregulation in the metabolic
homeostasis of the podocytes may result in podocyte injury and
glomerular disease. In diabetic nephropathy and other chronic
kidney diseases characterized by albuminuria there is an increase
in Nox4 and ROS production especially in podocytes [30–32]. In
human podocytes both Nox4 and Nox5 are expressed and upon
exposure to hyperglycemia Nox4 mRNA expression signiﬁcantly
increases but has no effect on Nox5 mRNA expression [33]. Sti-
mulation of human podocytes with Ang II upregulated Nox5 ex-
pression and increased ROS generation, while silencing of Nox5
blocked ROS and altered podocyte cytoskeleton and lead to a more
motile phenotype [34]. As mice do not express Nox5, transgenic
mice expressing human Nox5 in a podocyte-speciﬁc manner led to
early onset albuminuria, podocyte foot process effacement, and
elevated systolic blood pressure. Subjecting the mice to strepto-
zotocin-induced diabetes further exacerbated these changes [34].
Even in nondiabetic kidney injury, ROS plays a major role in pro-
gressive glomerular injury. The cytosolic p47phox subunit is a key
regulator of the assembly of Nox1 and Nox2 and its expression and
phosphorylation are upregulated during kidney injury. Deletion of
p47phox protected mice from albuminuria and glomerulosclerosis
in experimental models of focal segmental glomerulosclerosis
(FSGS) [35].
Hyperglycemia, transforming growth factor beta (TGFβ), and
Ang II promote podocyte apoptosis. Hyperglycemia results in ROS
production and podocyte apoptosis via sequential regulation of
Nox oxidases by cytochrome P450 of the 4A family (CYP4A). Up-
regulation of CYP4A leads to increased generation of 20-hydro-
xyeicosatetraenoic acid (20-HETE) and subsequent increase in
Nox1 and Nox4, and blocking 20-HETE production by inhibiting
CYP4A not only inhibited podocyte apoptosis in vitro but de-
creased oxidative stress, podocyte apoptosis, and proteinuria in a
diabetic model [36]. During hyperglycemia, Nox4 promotes po-
docyte cell death via activation of p53- and PUMA-dependent
apoptotic pathways [32]. Furthermore, the oxidative stress trig-
gered by hyperglycemia appears to be exacerbated by Nox4-de-
rived ROS that affects the balance between oxidants and anti-
oxidants through decreasing activity of key antioxidant enzymes
such as glutathione peroxidase and catalase [37].
Myoﬁbroblasts are the major matrix producing cells in ﬁbrosis
and are hallmarked by their expression of α-smooth muscle actin
(αSMA) and their contractile phenotype. The origins of myoﬁbro-
blasts are strongly debated at present [38], and the role of oxida-
tive stress in ﬁbrotic cell transformation has been reported in all
cells of origin [39–47]. Both Nox4 and Nox2 are expressed in
kidney ﬁbroblasts, and both homologs are upregulated by TGFβ,
implicating their importance and the role of ROS in activation of
the proﬁbrotic phenotype. Upon TGFβ activation, Nox4 expressionlevels greatly exceed Nox2 and siRNA inhibition of Nox4 sub-
stantially inhibits αSMA and extracellular matrix production
[48,49]. TGFβ binds to a receptor on the cell surface and forms a
complex of subunits called TGFR1 and TGFR2. Both TGFR1 and
TGFR2 activate serine/threonine kinases that subsequently signal
through the Smad family of transcription factors [50,51]. However,
unlike cardiac and lung myoﬁbroblasts where Nox4 acts upstream
of Smad2/3 [52,53], Nox4 is positioned downstream of Smad3 and
proximal to ERK in kidney myoﬁbroblast activation and extra-
cellular matrix production [49]. A recent study by Manickam and
colleagues demonstrated that in kidney myoﬁbroblasts inhibition
of RhoA and Rho A kinase (ROCK) reduced TGFβ stimulation of
Nox4 protein, NADPH oxidase activity, and myoﬁbroblast activa-
tion suggesting that RhoA/ROCK is upstream of Nox4 myoﬁbro-
blast signaling. Interestingly, RhoA/ROCK seems to act via in-
creasing the expression of polymerase (DNA-directed) δ-interact-
ing protein 2 (Polydip2), a newly discovered Nox4 enhancer pro-
tein [43]. Furthermore, a recent study by Hecker and colleagues
suggests that the persistent ﬁbrosis in aging may be related to a
redox imbalance between Nox4 and the antioxidant response
protein nuclear factor (erythroid derived-2)-related factor 2 (Nrf2).
Lung ﬁbroblasts from aged mice showed sustained expression le-
vels of Nox4 and an impaired capacity to induce Nrf2. In ﬁbro-
blasts from human subjects with idiopathic pulmonary ﬁbrosis
(IPF), Nox4 mediated a senescent and apoptotic resistant pheno-
type and genetic and pharmacologic targeting of Nox4 in aged
mice showed a reversal of established tissue ﬁbrosis [53]. You et al.
recently showed that NOX4 is a major mediator of diabetes-asso-
ciated glomerular dysfunction through targeting of renal fumarate
hydrolase, which increases fumarate levels. These authors propose
that fumarate is a key link connecting metabolic pathways to
diabetic kidney disease pathogenesis, and measuring urinary fu-
marate levels may have application for monitoring renal NOX4
[54]. Thus, Nox4 may serve as viable redox-sensitive target for
modulation of ﬁbrosis and diabetic kidney disease [55,56].
The role of Nox4 in renal tubular cells, however, has been more
controversial. Several studies have demonstrated that tubular
toxins such as glycated albumin and the uremic toxins indoxyl
sulfate and p-cresyl sulfate, trigger Nox-dependent ﬁbrogenic
pathways [57–61]. During the progressive loss of glomerular ﬁl-
tration, there is increasing inability of the kidney to remove ure-
mic toxins from the bloodstream. Particular attention has been
paid to protein bound uremic toxins in the prototype group of
phenols and indoles. Both indoxyl sulfate and p-cresyl sulfate have
been shown to accumulate in patients with progressive chronic
kidney disease and have been linked with increasing cardiovas-
cular mortality [62–65]. A recent study by Watanabe and collea-
gues [60] demonstrated that Nox4- and p22phox-based NADPH
oxidase derived ROS is a signiﬁcant mediator of p-cresyl sulfate-
dependent human tubular cell damage and increased expression
of inﬂammatory cytokines and proﬁbrotic factors. The study also
showed that accumulation of p-cresyl sulfate contributes to renal
tubular injury and extracellular matrix deposition in the 5/6 ne-
phrectomized rat model of CKD. However, studies by Babelova and
collegues [66] and Nlandu Khodo and colleagues [67] demon-
strated that global or cell-speciﬁc transgenic deletion of Nox4 in
several experimental models of chronic kidney injury did not re-
duce ﬁbrosis and in some cases resulted in increased tubular
apoptosis and oxidative stress and suggested that Nox4 in certain
instances of tubular injury was protective. Possible explanations to
these conﬂicting results from the studies discussed above could be,
at least in part, attributed to: (1) the importance of Nox4-depen-
dent ROS in homeostasis and early response to injury; (2) different
models of diabetes [33]; (3) the genetic manipulation used to
generate the global or cell speciﬁc knockouts;and (4) another ex-
ample of where genetic mouse models do not accurately represent
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of Nox may be a preferred approach than genetic manipulation to
study its utility in clinical studies.3. Neutralizing the oxidant response
The ability to reduce or remove ROS and RNS by endogenous
antioxidant enzymes is a key step in limiting tissue injury and
modulating redox sensitive pathways. During both acute and
chronic injury, many intracellular and extracellular antioxidant
systems become depleted resulting in increased oxidative stress
within the tissue. Several antioxidant defense systems have
evolved to detoxify speciﬁc free radicals.
3.1. Protein thiols
A thiol is a compound that contains the functional group – SH
(reduced) and can be oxidized to sulfenic acid resulting in disulﬁde
formation (oxidized). Thiol groups react with almost all physio-
logic oxidants and serves as a key antioxidant buffer for both in-
tracellular and tissue reduction/oxidation (redox) state [68]. Redox
reactions of thiol proteins are thought to be a major mechanism by
which reactive oxidants integrate into the cellular signal trans-
duction pathways [69–73]. Thiol proteins are well suited as targets
because cysteine residues are sensitive to oxidation, and changes
in enzymatic activity or binding characteristics due to oxidation
provide a mechanism for transmission of the signal. Reactive thiols
(–SH) in proteins are subject to a wide array of modiﬁcations in
oxidation state. Cysteine residues (HO2CCH(NH2)CH2–SH) in pro-
teins and enzymes serve important roles in cell signaling, protein-
protein interactions, substrate and metal binding, and catalysis.
[5,68]. It has been proposed that approximately 0.5% of all cysteine
residues in the proteome are subject to continuous and reversible
oxidation–reduction cycles and that this redox cycling controls
many aspects of structure and function in cells [74,75]. As our
understanding of signaling networks has become more sophisti-
cated, it has become evident that key regulators play essential
roles in multiple outcomes that are context dependent. For ex-
ample, a recent study by Numajiri and colleagues demonstrated
that phosphatase with sequence homology to tensin (PTEN) is
highly sensitive to relative low concentrations of NO and that its
enzymatic activity is inhibited by the resulting S-nitrosylation
(SNO) of Cys-83. The authors further demonstrated that at low
(physiologic) concentrations of NO, SNO-PTEN is formed and en-
hanced Akt phosphorylation, whereas high (pathologic) con-
centrations of NO lead to SNO-Akt and inhibited its function [76].
The reversible oxidation of cysteine residues on cell signaling
enzymes such as protein-tyrosine phosphatase illustrate how the
glutathione/thioredoxin system modulates oxidant-mediated cell
signaling pathways [77,78]. The three major biological thiol/dis-
ulﬁde couples include glutathione (GSH/GSSG), thioredoxin, and
cysteine containing proteins (R-Cys/R-CysSS). The micromolar
concentrations of thioredoxin compared to millimolar GSH con-
centrations could suggest that thioredoxin may be used for spe-
ciﬁcity of signaling or other highly critical functions while GSH is
used more globally for detoxiﬁcation and redox buffering [6]. Ex-
tracellular thiols also constitute an important component of anti-
oxidant defense and when depleted could result in tipping the
redox equilibrium toward increased levels of systemic oxidative
stress. The plasma protein reduced thiols (located primarily on the
albumin molecule) are depleted in patients with AKI and are thus
not able to participate in antioxidant defense [79]. Furthermore,
although protective reduced thiols are depleted in kidney injury,
oxidized thiols that include homocysteine and cysteine accumu-
late and may have toxic effects on the endothelium [80]. Studies inour lab have demonstrated that small molecule thiols such as cy-
steamine bitartrate have signiﬁcant antiﬁbrotic properties. Ad-
ministration of cysteamine bitartrate blocked ﬁbrosis progression
through reducing ROS production, limiting myoﬁbroblast activa-
tion, and myoﬁbroblast proliferation in vitro and in vivo and may
serve as a novel adjunctive antiﬁbrotic therapeutic agent [40].
3.2. Reduction of hydrogen peroxide
Peroxiredoxins, glutathione peroxidase, thioredoxin reductase,
and catalase represent an important group of enzymes that reduce
hydrogen peroxide. Thiol proteins likely represent an important
partner in the ability of these enzymes to limit the oxidative da-
mage of H2O2. For example, intracellular recycling of oxidized
glutathione peroxidase by GSH and oxidized peroxiredoxin by
thioredoxin enable these enzymes to inactivate greater amounts of
H2O2. The thioredoxin system (thioredoxin, thioredoxin reductase,
and peroxiredoxin) are ubiquitous and abundant proteins, with
different family members distributed through the cytoplasm, mi-
tochondria, and other cell compartments [81]. These thioredoxin
proteins are highly abundant in the renal tubules [82], but it's role
in CKD is not known. Catalase is also a key enzyme in antioxidant
defense in the kidney during injury. Studies of progressive kidney
disease in catalase-deﬁcient mice demonstrated that loss of cata-
lase buffering capacity leads to an increase in oxidative products
and more severe renal ﬁbrosis [47,83].
3.3. Redox regulation of mitochondrial ROS
After an ischemic or toxic insult, dysfunction of tubular epi-
thelial cells plays a key role in the evolution of AKI. Central to
tubular injury is mitochondrial dysregulation manifesting as a
reduction in cell respiration and ATP production [84–86]. Mi-
tochondrial function rests on a complex molecular machinery of
ﬁnely tuned and balanced by regulatory proteins of two opposing
forces ﬁssion and fusion [87,88]. In experimental AKI, ﬁssion
predominates, resulting in mitochondrial fragmentation, outer
membrane permeabilization, and release of apoptogenic factors
which together with ROS overproduction determine tubular cell
injury and apoptosis [85,89].
Homologs of the Saccharomyces cerevisiae, sirtuins, promote
longevity in many organisms and are an evolutionarily conserved
family comprising 7 proteins with NADþ-dependent deacetylase
activity in mammals, 3 of which (SIRT3–SIRT5) are mainly loca-
lized in the mitochondrion [90]. SIRT3 is the major mitochondrial
deacetylase that maintains basal ATP levels by direct physical as-
sociation with complex I and the activation of FoF1ATPase, as well
as ROS homeostasis through the regulation of detoxifying enzymes
[90–93]. SIRT3 overexpression protects cells against Bax-mediated
apoptosis, acting on NF-κB downstream target genes such as
manganese SOD (MnSOD) and Bcl2, thus making cells resistant to
H2O2–mediated cell injury [94]. Elevated expression levels of
SIRT3 in the kidney reduces ROS and ameliorates mitochondria
dynamics that translate into the longevity phenotype in mice de-
ﬁcient for angiotensin II type 1 receptor [95]. In cisplatin tubular
injury models, increased oxidative stress and mitochondrial frag-
mentation are associated with reduced levels of SIRT3. Treatment
with an AMPK agonist or the antioxidant agent acetyl-L-carnitine
(ALCAR) restored SIRT3 levels, improved renal function, and de-
creased tubular injury in wild-type animals but had no effect on
SIRT3-deﬁcient mice. SIRT3-deﬁcient mice had more severe AKI
thanwild-type animals and died. In proximal tubular cells, SIRT3 is
critical in preserving mitochondrial integrity by preventing dyna-
min-related protein-dependent (DRP1-dependent) ﬁssion, loss of
membrane potential, and PTEN-induced putative kinase 1-related
(PINK1-related) mitophagy [96]. Therapeutic agents to augment
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promise not only for AKI but for CKD as well.4. Biomarkers of pathologic oxidant pathways
During disease progression, there are several key oxidant
pathways that lead to the excessive generation of oxidative in-
termediates. Amino acids and lipids serve as natural targets of
these pathways and can serve as biomarkers of organ injury in
addition to serving as a ROS/RNS intermediate.
4.1. Myeloperoxidase
Myeloperoxidase (MPO) which is present in phagocytes can be
used to generate several oxidative intermediates: H2O2 can be
used by MPO to convert chloride ion to hypochlorous acid (HOCl)
[97,98]; and oxidation of NO with oxygen yields nitrite (NO2)
which MPO converts to nitrogen dioxide radical (NO2), a potent
nitrating intermediate [99,100]. Lipoproteins oxidized by MPO
have been detected in human atherosclerotic lesions [101–104]. In
clinical studies, MPO levels correlate with prospective mortality
risk in subjects on maintenance hemodialysis [105], and MPO-
oxidized LDL was noted to be elevated in the dialysis patients in a
different study [106]. While traditionally associated with auto-
immune vasculitic renal disease, more recent evidence point out
that MPO-mediated oxidation is a key element in diabetic kidney
disease and CKD progression [107–109]. It may also in part med-
iate increased cardiovascular morbidity in CKD patients [110,111].
4.2. Mitochondrial electron transport
Mitochondrial overproduction of O2 and the subsequent
dismutation to H2O2 in diabetic tissues can lead to oxidant injury.
Both hyperglycemia and excess free fatty acids can induce mi-
tochondrial dysfunction and lead to excess O2 production [112].
Moreover, O2 inhibits glyceraldehyde phosphate dehy-
drogenase, a key glycolytic enzyme whose inactivity could make
upstream metabolites accumulate. Such inhibition of glycolysis
might promote end-organ damage by diverting metabolites into
the hexosamine pathway or stimulating the polyol and diacylgly-
cerol-protein kinase C pathways. Exposing endothelial cells to
exogenous oxidants leads to mitochondrial damage and can aug-
ment O2 production, a mechanism whereby oxidative stress
perpetuates oxidative stress in a pathologic feedforward pathway
[113]. Benfotiamine, a lipid-soluble thiamine analog that inhibits
these pathways by activating transketolase, an enzyme in the
pentose pathway shunt, can prevent complications from experi-
mental diabetes in animal models [114]. Recent evidence has cast
some doubts on this hypothesis, but attribute Nox4 activity to
diabetic kidney disease progression [115].
4.3. Uncoupled eNOS
NO synthesized by eNOS in endothelial cells and its uncoupling
plays a major role in diabetes, hypertension, and CKD. Oxidation of
its cofactor tetrahydrobiopterin (BH4) [116] uncouples eNOS which
then transfers electrons to molecular oxygen, generating O2
[117] and subsequent ONOO . Peroxynitrite is a potent oxidant
that converts tyrosine residues to 3-nitrotyrosine, which serves as
a biomarker for the activation of the RNS. Indeed, elevated levels
of nitrotyrosine have been identiﬁed in mouse models of diabetic
kidney disease and neuropathy [118,119]. An alternative mechan-
ism for uncoupling eNOS involves overproduction of angiotensin
II, which can induce dihydrofolate reductase deﬁciency. Dihy-
drofolate reductase maintains BH4 in its reduced form, andtherefore its deﬁciency uncouples eNOS. Administering BH4 im-
proves endothelium-dependent vasodilation in experimental ani-
mals and humans with those conditions [120]. Studies of eNOS
deﬁcient mice reported from two separate groups show dramatic
histopathology and decline in glomerular ﬁltration rate in settings
of diabetic hyperglycemia attesting to the importance of this
pathway in diabetic nephropathy [121,122].
The uncoupled eNOS has also been suggested as a key mediator
of both vascular and renal injury in Fabry's disease, a lysosomal
storage disorder secondary to a deﬁciency in alpha-galactosidase A
[123], and 3-nitrotyrosine, might be a novel biomarker of Fabry
vasculopathy [124].
4.4. Glycoxidation
The glycoxidation pathway is particularly relevant in high-
glucose states such as diabetes mellitus, a well-established cause
of CKD. In its open-chain form, glucose has a carbonyl group that is
a target of oxidative chemistry. Glucose auto-oxidization has been
reported to mediate covalent linkage of glucose to amino groups
on proteins by a hydroxyl radical-dependent mechanism [125].
Glucose also reacts nonenzymatically with proteins to form the
reversible Schiff base adduct, which subsequently can rearrange
itself into the stable Amadori product and advanced glycosylation
end products (AGE). In vitro, free metal ions catalyze steps in a
nonenzymatic glycoxidation pathway that generates AGE pro-
ducts. Metal-catalyzed hydroxyl radical formation can peroxidize
lipids and convert phenylalanine residues of proteins into isomers
of tyrosine such as ortho-tyrosine and meta-tyrosine [126–128].
Reduced, redox-active metal ions (Mnþ) such as Fe2þ and Cu1þ
generate hydroxyl radical (HO) when they react with H2O2. AGEs
can damage tissues through a number of mechanisms, including
generation of oxidizing intermediates, formation of immune
complexes, interaction with a cellular receptor called RAGE (Re-
ceptor for AGE), and induction of cytokine release [129,130]. Al-
though RAGE binds to AGE-modiﬁed proteins in vitro with high
afﬁnity, its ligands in vivo are unclear. High levels of AGEs accu-
mulate in renal failure, even in nondiabetic patients, and this
process reverses after renal transplantation, implicating the kid-
neys in AGE production and/or clearance [131–134]. Many studies
have shown that age-adjusted levels of pentosidine and
Nε-carboxymethyllysine, two known AGE products, correlate with
the development of diabetic complications [127,135–138].
4.5. Glucose-polyunsaturated fatty acids
Glucose can also generate reactive intermediates by interacting
with polyunsaturated fatty acids (PUFA). When incubated with
LDL or a control protein such as ribonuclease (RNAse), pathophy-
siologically relevant concentrations of glucose induce formation of
oxidatively-modiﬁed amino acids in LDL even in the absence of
free metal ions; in contrast, glucose exposure did not increase
levels of oxidized amino acids in RNAse [139]. This study indicates
that glucose is capable of generating a species resembling the
hydroxyl radical by a carbonyl/PUFA pathway, a potential me-
chanism for localized oxidative stress in tissues vulnerable to
diabetic damage [139].
4.6. Detection of oxidized biomolecules in vivo
ROS and RNS intermediates are difﬁcult to detect in vivo be-
cause they are extremely short-lived due to their high reactivity
with substrates; however, these oxidized substrates may serve as
biomarkers for the activation of relevant oxidative pathways. Im-
munohistochemistry and dihydroethidium ﬂuorescence have been
extensively used to study oxidation-speciﬁc epitopes and oxidant
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to provide epitope-speciﬁc structural data can localize oxidative
events to cell types or to subcellular locations. However, they are
nonspeciﬁc as antibodies can bind to structurally similar com-
pounds and, at best, only semiquantitative. Mass spectrometry
(MS) offers a highly sensitive and speciﬁc approach to quantify
oxidative biomarkers. When combined with isotope dilution, in
which a labeled internal standard which is identical to the target
analyte except for the heavy isotope is added to the mixture, ac-
curate quantitation can be achieved.
4.7. Oxidized amino acid content correlates with degree of oxidative
stress in vivo.
To understand the molecular mechanisms that promote oxi-
dative stress in vivo, we ﬁrst identiﬁed the patterns of oxidation
products that are formed by well-characterized oxidant-generat-
ing model systems. The phenylalanine residues in proteins when
subjected to glycoxidation or hydroxyl radical damage form ortho-
tyrosine and meta-tyrosine. Oxidation reactions of tyrosine re-
sidues include cross-linking (to form oo′-dityrosine; mediated by
tyrosine radicals, ROS and RNS), chlorination (to form 3-chlor-
otyrosine; catalyzed by myeloperoxidase) and nitration (to from
3-nitrotyrosine; mediated by RNS). Quantifying these unnatural
amino acids characterizes the underlying oxidant pathway op-
erative in target tissue. Using a combination of free radical gen-
erating systems in vitro and studying biospecimens from animal
models of disease and humans, we and others deﬁned patterns of
these oxidative markers that accurately indicate pathways of oxi-
dation that are activated [101,104,118,119,123,124,139–157]. Si-
milar techniques can be used to accurately quantify oxidatively
modiﬁed bioactive lipids [118,119,149,152,158,159].5. Conclusions
Using a wide variety of different biomarkers of increased oxi-
dative stress status, numerous laboratories around the world have
now unequivocally demonstrated that CKD and ESKD is a state of
increased oxidative stress due to an overproduction of ROS and a
diminished antioxidant reserve. This leads to a dysregulation in
redox signaling pathways that augment kidney injury and pro-
mote ﬁbrogenesis. Disappointingly, traditional approaches with
broad antioxidants to reduce systemic oxidant stress have not
resulted in signiﬁcant alterations in limiting or reversing disorders
in which oxidative stress has been implicated by model system
studies. Such observations highlight the importance of doc-
umenting that a proposed antioxidant intervention actually in-
hibits oxidative reactions in vivo [160–162]. The ability to accu-
rately quantify amino acid and lipid oxidation markers in tissue
samples, plasma, and urine can provide a means of monitoring the
efﬁcacy of therapeutic interventions, in addition to providing
mechanistic insights into disease pathogenesis. Potential therapies
interrupting only reactive pathways that are activated in target
tissues are likely to be beneﬁcial in modulating kidney injury and
hold the promise of attenuating the relentless progression of CKD.Acknowledgements
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